Patents Represented by Attorney Diana K. Sheiness
  • Patent number: 6884598
    Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: April 26, 2005
    Assignee: Immunex Corporation
    Inventor: William C. Dougall
  • Patent number: 6838262
    Abstract: Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate an immune response. The ligands are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: January 4, 2005
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent J. Galibert
  • Patent number: 6740522
    Abstract: Provided herein are antibodies that bind human RANKL polypeptides.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: May 25, 2004
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 6649164
    Abstract: Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to enhance the functional capacity of dendritic cells.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: November 18, 2003
    Assignee: Immunex Corporation
    Inventor: Eugene Maraskovsky
  • Patent number: 6562948
    Abstract: Provided herein are isolated antibodies that specifically bind a RANK polypeptide.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 13, 2003
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 6537763
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: March 25, 2003
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky
  • Patent number: 6528482
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: March 4, 2003
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Patent number: 6448035
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: September 10, 2002
    Assignee: Immunex Corporation
    Inventor: David J. Cosman
  • Patent number: 6419929
    Abstract: Isolated recombinant RANK-L polypeptide DNAs encoding RANK-L polypeptide, and pharmaceutical compositions made therefrom, are disclosed. The isolated RANK-L polypeptide can be used to regulate an immune response. The RANK-L polypeptide is also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: July 16, 2002
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 6384203
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against LIR polypeptides. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: May 7, 2002
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Luis G. Borges
  • Patent number: 6309632
    Abstract: Provided are methods for reducing the HIV viral load in HIV-infected patients by administering human GM-CSF. The GM-CSF is administered in conjunction with at least two nucleoside reverse transcriptase inhibitors.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: October 30, 2001
    Assignee: Immunex Corporation
    Inventor: Jan M. Agosti
  • Patent number: 6274175
    Abstract: Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo.
    Type: Grant
    Filed: November 17, 1999
    Date of Patent: August 14, 2001
    Assignee: Immunex Corporation
    Inventors: Wayne R. Gombotz, Dean K. Pettit, Susan C. Pankey
  • Patent number: 6271349
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: August 7, 2001
    Assignee: Immunex Corporation
    Inventors: William C. Dougall, Laurent Galibert
  • Patent number: 6242213
    Abstract: Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate an immune response. The ligands are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: June 5, 2001
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson